At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 94 enrolled
Drug / intervention
denosumab +1 moredrug
Likely dose
denosumab 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Denosumab And Teriparatide Administration Study (DATA)
In Brief
A Phase 2 clinical trial evaluating denosumab and teriparatide for Osteoporosis. Completed, enrolled 94 participants across 1 site.
Detailed Summary
The aim of this study is to determine whether denosumab (an FDA-approved osteoporosis therapy), in combination with teriparatide (an FDA-approved osteoporosis therapy), will increase bone mineral density more than either one alone in postmenopausal osteoporotic women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
CollaboratorsAmgen
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJun 2009
Primary CompletionDec 2016
TodayJul 2026
First PostedJun 23, 2009
Enrollment StartJun 1, 2009
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 17.0 years ago
Interventions
denosumabdrug
denosumab: 60 mg SC every 6 months
teriparatidedrug
teriparatide: 20 mcg SC QD